2024
Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States
Park H, Gonsalves G, Tan S, Kelly J, Rutherford G, Wachter R, Schechter R, Paltiel A, Lo N. Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. Nature Communications 2024, 15: 1883. PMID: 38448400, PMCID: PMC10917753, DOI: 10.1038/s41467-024-45549-9.Peer-Reviewed Original ResearchConceptsSevere COVID-19Risk of severe COVID-19COVID-19 booster vaccinationBooster vaccinationHigh-risk populationAbsolute annual riskWaning of protectionImmunocompromised populationsFrequent boostingOlder age groupsAnnual boosterImmune evasionImmunocompromised personsPublic health needsPublic health guidanceRisk groupsFrequent boostersImmune statusRisk factorsFrequency of booster vaccinationHealth needsHealth guidanceCompare frequenciesAge groupsVaccine
2011
The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results
Andersson KM, Paltiel AD, Owens DK. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results. Vaccine 2011, 29: 6107-6112. PMID: 21736912, PMCID: PMC3164284, DOI: 10.1016/j.vaccine.2011.06.076.Peer-Reviewed Original ResearchConceptsBooster vaccinationHIV prevalencePopulation coverage levelsRV144 trialHIV vaccineCondom useContinuous vaccinationHIV vaccine regimenPopulation HIV prevalenceDuration of protectionCoverage levelsRV144 vaccineVaccine regimenHIV infectionHeterosexual transmissionModest efficacyVaccine efficacyUnvaccinated populationVaccination strategiesPartial efficacyEfficacy vaccineLower riskVaccinationBooster strategyVaccine